Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
In the February issue, Dr Playfer highlighted ageism in Parkinson’s disease (PD) trials.1 This is only one reason why neurologists with an interest in PD might look back with embarrassment. He describes the CALM-PD, RQP 056 and CBS 09 studies as excellent, yet they all failed to answer the basic clinical question for even the recruited populations: with which drug should we start treatment for PD, an agonist, L-dopa or an MAOB inhibitor? The trials showed that agonists caused fewer …